Arcturus Therapeutics Holdings Inc.

ARCT

Explore Our Financial Data > Companies > Arcturus Therapeutics Holdings Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ARCT
CIK0001768224
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121
Website arcturusrx.com
Phone8589002660
CEOJoseph E. Payne
Employees180

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$143.68 million
Pre-Tax Income$-68.57 million
Net Income$-68.20 million
Net Income to Common$-68.20 million
EPS$-2.52
View All
Balance Sheet
Cash$216.95 million
Assets$331.78 million
Liabilities$98.03 million
Common Equity$233.76 million
Liabilities & Equity$331.78 million
View All
Cash Flow Statement
Net Income$-68.20 million
Cash From Operating Activities$-89.33 million
Cash From Investing Activities$-545,000.00
Cash From Financing Activities$18.42 million
Change in Cash$-71.45 million
View All
Calculations
NOPAT$-57.46 million
EBITDA$-65.13 million
Price to EarningsN/A
Price to Book$1.43
ROE-27.40%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

SAN DIEGO, July 24, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025

Article Link

Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO, July 23, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:

Article Link

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

SAN DIEGO, June 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia crise

Article Link

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO, June 23, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will host a virtual KOL presentation of ARCT-810 Phase 2 interim data for Ornithine Transcarbamylase (OTC) deficiency on Monday, June 30, 2025, at 12:00 p.m. ET. The Company will issue a press release summa

Article Link

Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet

The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Article Link